Gastroenterology

2019/04/09MEDICAL UPDATE

Translational science in IBD

Translational research is playing an increasingly vital role for bridging the gap between, on the one hand, basic science and on the other, clinical studies and routine clinical practice. Among the findings presented in a digital oral presentation session at ECCO 2019 were new insights into the mechanism of action of vedolizumab and potential new therapeutic targets for treating fibrosis and strictures in IBD...

READ MORE

2019/04/09MEDICAL UPDATE

IBD around the world

IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation...

READ MORE

2019/03/13MEDICAL UPDATE

Metabolic profiling

Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to finding new disease markers and targets for intervention.

READ MORE

2019/03/13MEDICAL UPDATE

VARSITY: head to head comparison of adalimumab vs vedolizumab in UC

The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab. More head-to-head trials are due to be completed shortly and the results are expected to be as important for clinical practice as the SONIC, CALM and NOR-SWITCH studies.

READ MORE

2019/03/11MEDICAL UPDATE

ECCO 2019 Highlights

The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber (Germany), Professor David Rubin (USA), Dr Filip Baert (Belgium) and Professor William Sandborn (USA) discuss their highlights from the meeting including the long-awaited head to head VARSITY study comparing adalimumab with vedolizumab and the maintenance data from the UNIFI study for ustekinumab. 

READ MORE

2018/12/05MEDICAL UPDATE

Advanced Stage Disease

As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced without loss of effect. Experts presented updates on three of the landmark studies …

READ MORE

2018/10/02MEDICAL UPDATE

DDW 2018: Predicting who will get IBD

Interview by Hannah Chatfield To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational symposium at DDW 2018, speakers discussed the role of genetics, diet and environment in IBD aetiology.

READ MORE

2018/10/02MEDICAL UPDATE

DDW 2018: Treatment of perianal fistulising disease

By Maria Dalby Perianal fistulas remain a debilitating complication for CD patients, with high levels of morbidity and impact on quality of life. Several abstracts and posters at DDW 2018 addressed the clinical management of perianal fistulas in CD.

READ MORE

2018/10/02MEDICAL UPDATE

DDW 2018: IBD Study Updates

Interview by Hannah Chatfield This article summarises some of the key study updates presented at DDW 2018.

READ MORE

2018/03/01MEDICAL UPDATE

ECCO 2018: Returning to a normal life with IBD

By Maria Dalby (article) and Peter Mas Mollinedo (interviews) Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term impact of the disease. Patient empowerment and patient-centred care are essential for reducing the burden of IBD; however, to achieve these clinicians must have a clear understanding of patients’ goals and perspectives...

READ MORE